AbbVie Stock (NYSE:ABBV)
Previous Close
$175.05
52W Range
$153.58 - $218.66
50D Avg
$200.45
200D Avg
$187.93
Market Cap
$316.82B
Avg Vol (3M)
$7.36M
Beta
0.54
Div Yield
$6.56 (2.65%)
ABBV Company Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|
| H U M I R A | $8.99B | $14.40B | $21.24B |
| VENCLEXTA | $2.58B | $2.29B | $2.01B |
| Linzess/Constella | $954.00M | $1.11B | $1.03B |
| Imbruvica | $3.35B | $3.60B | $4.57B |
| Restasis | $224.00M | $436.00M | $666.00M |
| Ozurdex | $494.00M | $472.00M | - |
| Vraylar | $3.27B | $2.76B | $2.04B |
| Ubrelvy | $1.01B | $815.00M | - |
| Botox Cosmetic | $2.72B | $2.68B | $2.62B |
| Juvederm Collection | $1.18B | $1.38B | $1.43B |
| Other Aesthetics | $1.28B | $1.23B | $1.29B |
| Alphagan/Combigan | $248.00M | $272.00M | $346.00M |
| Lumigan/Ganfort | $429.00M | $432.00M | $514.00M |
| Qulipta | $658.00M | $408.00M | - |
| Other Neuroscience | $338.00M | $276.00M | $475.00M |
| Duodopa | $447.00M | $468.00M | $458.00M |
| Botox Therapeutic | $3.28B | $2.99B | $2.72B |
| RINVOQ | $5.97B | $3.97B | $2.52B |
| SKYRIZI | $11.72B | $7.76B | $5.17B |
| Other Products | $3.03B | $3.04B | $4.14B |
| Other Eye Care | $847.00M | $803.00M | $1.18B |
| MAVYRET | $1.31B | $1.43B | $1.54B |
Fiscal year ends in Dec 24 | Currency in USD